Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
NCT00688415
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
33
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Lymphoma
Interventions
DRUG:
VTX-2337
Sponsor
Celgene